Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of single-dose GBI268 injection for postoperative local analgesia after unilateral open hallux valgus correction surgery
CTR20244972Phase 2Completed
- Sponsor
- Guangzhou Zhiyao Biotechnology
- Start
- Jan 2025
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GBI268 in postoperative pain (3 arms), sponsored by Guangzhou Zhiyao Biotechnology. Primary endpoint: Average area under the curve of pain intensity scores during movement and at rest over a specified period after completion of dosing. Started Jan 2025; status: completed.
02
Drugs
GBI268
03
Conditions
postoperative pain
Beyond the preview
Go deeper on CTR20244972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244972.